Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Aug 15;21(16):4674-85.
doi: 10.1016/j.bmcl.2011.06.096. Epub 2011 Jun 28.

The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH)

Affiliations
Review

The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH)

Katerina Otrubova et al. Bioorg Med Chem Lett. .

Abstract

A summary of the discovery and advancement of inhibitors of fatty acid amide hydrolase (FAAH) is presented.

PubMed Disclaimer

Figures

Figure 1
Figure 1
2-Octyl α-bromoacetoacetate and a more potent synthetic analogue.
Figure 2
Figure 2
Representative early inhibitors of FAAH.
Figure 3
Figure 3
Representative trifluoromethyl ketone inhibitors.
Figure 4
Figure 4
Representative initial α-ketoheterocycle inhibitors.
Figure 5
Figure 5
Characteristic modifications in the fatty acid side chain.
Figure 6
Figure 6
Representative C5 substituted α-ketooxazoles and structure of OL-135.
Figure 7
Figure 7
Plot of–Log Ki versus σp.
Figure 8
Figure 8
Representative exploration of the C2 acyl side chain.
Figure 9
Figure 9
Key variations of the central activating heterocycle.
Figure 10
Figure 10
Representative further conformational constraints in the C2 acyl side chain.
Figure 11
Figure 11
Additional classes of reversible FAAH inhibitors.
Figure 12
Figure 12
Recent classes of reversible FAAH inhibitors.
Figure 13
Figure 13
Additional reversible FAAH inhibitors.
Figure 14
Figure 14
β-Lactam FAAH inhibitors.
Figure 15
Figure 15
O-Aryl carbamates.
Figure 16
Figure 16
Representative carbamate hybrids.
Figure 17
Figure 17
Additional early carbamates.
Figure 18
Figure 18
Subsequent carbamate inhibitors.
Figure 19
Figure 19
Oxazole ketone/carbamate inhibitors.
Figure 20
Figure 20
Representative piperazine carbamates.
Figure 21
Figure 21
Tetrazole-based inhibitors.
Figure 22
Figure 22
Additional triazolopyridine and azole FAAH inhibitors.
Figure 23
Figure 23
Piperazine aryl urea inhibitors.
Figure 24
Figure 24
Piperidine/piperazine urea-based inhibitors of FAAH.
Figure 25
Figure 25
Additional urea inhibitors.
Figure 26
Figure 26
Tetrasubstituted urea inhibitor.
Scheme 1
Scheme 1
Carbamylation of active site Serine 241.
Scheme 2
Scheme 2
Carbamylation of active site Serine 241.
Scheme 3
Scheme 3
Activating conformational change of urea group.

Similar articles

Cited by

References

    1. Ezzili C, Otrubova K, Boger DL. Bioorg Med Chem Lett. 2010;20:5959. - PMC - PubMed
    1. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Science. 1992;258:1946.Review: Martin BR, Mechoulam R, Razdan RK. Life Sci. 1999;65:573.

    1. Cravatt BF, Lerner RA, Boger DL. J Am Chem Soc. 1996;118:580.Cravatt BF, Prospero–Garcia O, Suizdak G, Gilula NB, Henriksen SJ, Boger DL, Lerner RA. Science. 1995;268:1506.Lerner RA, Siuzdak G, Prospero Garcia O, Henriksen SJ, Boger DL, Cravatt BF. Proc Natl Acad Sci USA. 1994;91:9505.Review: Boger DL, Henriksen SJ, Cravatt BF. Curr Pharm Des. 1998;4:303.

    1. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Nature. 1996;384:83.Giang DK, Cravatt BF. Proc Natl Acad Sci USA. 1997;94:2238.Reviews: Patricelli MP, Cravatt BF. Vit Hormones. 2001;62:95.McKinney MK, Cravatt BF. Ann Rev Biochem. 2005;74:411.

    1. Egertova M, Cravatt BF, Elphick MR. Neuroscience. 2003;119:481. - PubMed
    2. Long JZ, LaCava M, Jin X, Cravatt BF. J Lipid Res. 2011;52:337. - PMC - PubMed

Publication types

LinkOut - more resources